Table 1 Comparison of patients with and without thrombosis according to demographic and clinical parameters

Age (years)*

55.1 ± 13.4

0

52.9 ± 13.7

55.4 ± 13.3

0.99

0.97–1.004

0.137

Male sex (%)

348 (55.6)

0

49 (68.1)

299 (54.0)

1.82

1.08–2.07

0.025

Smokers (%)

277 (46.8)

16

35 (51.5)

242 (46.2)

1.24

0.75–2.05

0.412

BMI¹ *

25.3 ± 4.7

7.7

25.6 ± 4.0

25.2 ± 4.8

1.01

0.96–1.07

0.598

Prior history of thrombotic events (%)

42 (6.8)

12.5

9 (12.7)

33 (6.9)

2.27

1.04–4.96

0.041

ECOG PS² (%)

0

102 (16.7)

13.3

17 (25.0)

85 (15.7)

0.71

0.53–0.94

0.017

1

256 (41.9)

30 (44.1)

226 (41.6)

2

182 (29.8)

17 (25.0)

165 (30.4)

3

48 (7.9)

3 (4.4)

45 (8.3)

4

23 (3.8)

1 (1.5)

22 (4.1)

Comorbidities

Total number **

1 (0–7)

1.9

1 (0–4)

1 (0–7)

0.85

0.67–1.08

0.193

Diabetes (%)

102 (17.4)

17.4

10 (14.5)

92 (17.8)

0.78

0.39–1.59

0.498

Hypertension (%)

156 (25.0)

17.4

14 (20.3)

142 (27.5)

0.67

0.36–1.25

0.208

Antiplatelet therapy (%)

33 (5.4)

1.9

5 (7.1)

28 (5.1)

0.71

0.26–1.89

0.488

HCT CI³ (%)

1 (0–9)

2.4

1 (0–4)

1 (0–9)

0.83

0.83 − 0.69

0.052

Khorana score (%)

0

112 (17.9)

11.5

13 (18.1)

99 (17.9)

0.94

0.66–1.32

0.708

1

322 (51.4)

39 (54.2)

283 (51.1)

2

184 (29.4)

19 (26.4)

165 (29.8)

3

8 (1.3)

1 (1.4)

7 (1.3)

Al Ani score (%)

0

317 (50.6)

0

30 (41.7)

287 (51.8)

1.26

0.90–1.78

0.185

1

296 (47.3)

40 (55.6)

256 (46.2)

2

0 (0.0)

0 (0.0)

0 (0.0)

3

8 (1.3)

2 (2.8)

6 (1.1)

4

5 (0.8)

0 (0.0)

5 (0.9)

COVID-19 (%)

59 (9.4)

11.6

7 (9.7)

52 (9.4)

1.04

0.45–2.38

0.931

⁴CNS involvement (%)

54 (20.5)

-

11 (30.6)

43 (18.9)

1.89

0.87–4.14

0.110

⁵WBC (normal: 3.6–10 × 10⁹/L) **

9.8 (0.4-473.2)

0

10.5 (0.7-211.6)

9.7 (0.4-473.2)

0.998

0.993–1.002

0.321

Platelet count (normal:150–400 × 10⁹/L)**

49 (1-726)

0

56 (1-220)

47 (1-726)

1.001

0.998–1.004

0.370

Hemoglobin (normal: 120–160 g/L)*

95.8 ± 17.8

0

97.0 ± 18.8

95.7 ± 17.4

1.004

0.991–1.018

0.542

⁶LDH (normal, 220–460 U/L)**

458 (105–8902)

9.4

384 (180–4150)

465 (105–8902)

1.000

0.999-1.000

0.170

Fibrinogen (normal: 2.2–5.5 g/L)**

5.4 (0.3–56.0)

5.2

5.6 (1.4–8.5)

5.3 (0.3–56.0)

0.928

0.821–1.048

0.229

INR (normal: 0.8–1.3%)*

1.22 ± 0.19

5.2

1.18 ± 0.17

1.23 ± 0.20

0.21

0.05–0.95

0.043

⁸APTT (normal: 25.1–36.5 s)*

29.2 ± 5.6

5.2

28.4 ± 4.2

29.3 ± 57

0.96

0.91–1.02

0.198

D dimer (normal: 0–0.5 µg/L)**

2.5 (0.1–158.0)

26.5

2.1 (0.3-100.8)

2.5 (0.1–158.0)

0.99

0.98–1.01

0.649

⁹ISTH DIC score ≥ 5 (%)

131 (41.3)

26.5

12 (28.6)

119 (43.3)

0.52

0.26–1.07

0.075

Blast peripheral blood (%)

16 (0–99)

-

15 (0–98)

17 (0–99)

0.99

0.98–1.003

0.182

FAB (%)

0

32 (5.3)

3.4

3 (4.3)

29 (5.4)

0.99

0.90–1.10

0.881

1

69 (11.4)

12 (17.4)

57 (10.6)

2

150 (24.8)

19 (27.5)

131 (24.4)

3

2 (0.3)

0 (0.0)

2 (0.4)

4

172 (28.4)

16 (23.2)

156 (29.1)

5

99 (16.4)

7 (10.1)

92 (17.2)

6

2 (0.3)

0 (0.0)

2 (0.4)

7

1 (0.2)

0 (0.0)

1 (0.2)

9

78 (12.9)

12 (17.4)

66 (12.3)

¹⁰ELN classification (%)

Good

66 (11.4)

-

8 (11.9)

55 (11.3)

0.88

0.58–1.33

0.529

Intermediate

330 (59.5)

42 (62.7)

288 (59.0)

High

162 (29.2)

17 (25.4)

145 (29.7)

¹¹FLT3 ITD positivity (%)

63 (19.9)

-

9 (20.9)

54 (19.7)

1.08

0.49–2.38

0.852

¹²NPM1 positivity (%)

59 (24.4)

-

11 (33.3)

48 (23.0)

1.68

0.76–3.70

0.201

¹³CD56 positivity (%)

175 (33.1)

22.3

19 (29.7)

156 (33.5)

0.84

0.47–1.48

0.539

CD13 positivity (%)

510 (93.1)

22.3

59 (90.8)

451 (93.4)

0.7

0.28–1.74

0.440

CD34 positivity (%)

382 (69.5)

22.3

42 (64.6)

340 (70.1)

0.78

0. 45-1.34

0.368

CD33 positivity (%)

512 (93.1)

22.3

60 (90.9)

452 (93.4)

0.71

0.28–1.76

0.458

CD117 positivity (%)

482 (87.8)

22.3

55 (87.8)

427 (87.9)

0.95

0.43–2.09

0.899

CD7 positivity (%)

126 (23.8)

22.3

11 (17.5)

115 (24.6)

0.65

0.33–1.28

0.213

CD15 positivity (%)

178 (34.0)

22.3

21 (33.9)

157 (34.0)

0.99

0.57–1.74

0.986

CD19 positivity (%)

49 (9.5)

22.3

6 (9.8)

43 (9.5)

1.04

0.42–2.56

0.932

¹⁴CVL inserted (%)

519 (82.9)

11.5

68 (94.4)

451 (81.4)

3.88

1.38–10.89

0.010

Therapy type (%)

Intensive

453 (72.4)

11.3

60 (83.3)

393 (70.9)

2.05

1.07–3.91

0.030

Non-intensive

173 (27.6)

12 (16.7)

161 (29.1)